Satwik Kuppili

Dr. Satwik Kuppili


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
JUJahnavi Udaikumar
Jahnavi Udaikumar
RNRithish Nimmagadda
Rithish Nimmagadda
VLVindhya vasini Lella
Vindhya vasini Lella
KAKesava Manikanta Achuta
Kesava Manikanta Achuta
SKSatwik Kuppili
Satwik Kuppili
RSRaiya Sarwar
Raiya Sarwar
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly encompassed under nonalcoholic fatty liver disease (NAFLD), is a growing global health burden associated with progression to cirrhosis and hepatocellular carcinoma. Resmetirom, a thyroid hormone receptor-β (THR-β) agonist, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), have emerged as promising agents targeting distinct metabolic and inflammatory pathways. This systematic review compares the safety and efficacy of resmetirom and semaglutide in MASLD. Methods: We conducted a comprehensive search of PubMed, Embase, and Google Scholar for randomized controlled trials and clinical studies published between January 2014 and April 2025, following PRISMA guidelines. Studies assessing the efficacy and safety of resmetirom and/or semaglutide in MASLD or NASH were included. Data extraction was performed by two independent reviewers, and a narrative synthesis was undertaken due to the heterogeneity in study design and outcome measures. Results: Fourteen studies encompassing over 4500 patients were analyzed. Resmetirom demonstrated consistent reductions in hepatic fat (≥30% in >50% of patients) and improvements in fibrosis (≥1 stage in up to 26.4% of patients), as evidenced in the MAESTRO-NASH trial. Semaglutide achieved higher rates of NASH resolution (up to 62.9%) without worsening fibrosis, especially among patients with type 2 diabetes or obesity, although fibrosis improvement was less consistently observed. Resmetirom was well tolerated with low discontinuation rates, while semaglutide was associated with more frequent, yet manageable, gastrointestinal adverse events. Conclusions: Both resmetirom and semaglutide show therapeutic potential for MASLD. Resmetirom offers more consistent antifibrotic effects, while semaglutide excels in NASH resolution and metabolic improvement. The absence of direct comparative trials underscores the need for future head-to-head studies to guide tailored treatment strategies in MASLD management.


26 April 2023 in New Microbes and New Infections
Verified
Journal Article
Open access
TSTarun Kumar Suvvari
Tarun Kumar Suvvari
AMAroop Mohanty
Aroop Mohanty
SKSatwik Kuppili
Satwik Kuppili
VKVenkataramana Kandi
Venkataramana Kandi
Bijaya Kumar PadhiBijaya Kumar Padhi
Bijaya Kumar Padhi
Ranjit SahRanjit Sah
Ranjit Sah

19 March 2025 in Cureus
Verified
Journal Article
Open access
NNNirupam Nadella
Nirupam Nadella
SKSatwik Kuppili
Satwik Kuppili
RSRhythm L Shukla
Rhythm L Shukla
KKKorvi N Kumar
Korvi N Kumar
ASAdil M Siddiqui
Adil M Siddiqui
MMMadhukar Madineni
Madhukar Madineni
A four-year-old boy presented with a four-week history of hematuria, melena, and ecchymoses on his forehead, arm, and back, as well as upper respiratory symptoms. The physical examination revealed diffuse purpura on the lips, pallor, and several hyperpigmented spots. Laboratory results showed microcytic hypochromic anemia, neutropenia, lymphocytosis, and severe thrombocytopenia. A peripheral smear revealed giant platelets and a bone marrow biopsy revealed enhanced megakaryocytes with aberrant maturation. Despite the initiation of prednisolone medication, the patient experienced generalized tonic-clonic seizures and diminished consciousness (Glasgow Coma Scale: 4/15). Neuroimaging revealed a left-sided intracerebral hemorrhage with a midline shift, requiring an immediate decompressive craniotomy. Early detection and rapid interdisciplinary management are critical for improving outcomes in these life-threatening conditions.

10 December 2025 in The National Medical Journal of India
Verified
Journal Article
Open access
PDF file
VLVindhya Vasini Lella
Vindhya Vasini Lella
SKSatwik Kuppili
Satwik Kuppili
NMN. Sachidananda Moorthy
N. Sachidananda Moorthy
Undergraduate medical students and their interests beyond medicine

3 November 2026 in GLOBAL JOURNAL OF MEDICAL STUDENTS
Verified
Journal Article
Open access
PDF file
SDShreya Durve
Shreya Durve
SKSatwik Kuppili
Satwik Kuppili
VLVindhya Vasini Lella
Vindhya Vasini Lella
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an established class of antidiabetic agents that have gained expanding indications in obesity and metabolic syndrome management. By mimicking endogenous incretin activity, these agents enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying and promote satiety, resulting in improved glycaemic control and clinically meaningful weight reduction. Agents within this class – including semaglutide, liraglutide, dulaglutide, exenatide and tirzepatide – have demonstrated reductions in glycated haemoglobin, body weight and major adverse cardiovascular events in patients with type 2 diabetes mellitus (T2DM). Emerging evidence further highlights their role in hepatic steatosis improvement and cardiometabolic risk modification. Obesity is a well-established risk factor for chronic kidney disease (CKD), contributing through mechanisms such as glomerular hyperfiltration, renin–angiotensin–aldosterone system activation, lipotoxicity, hypertension and worsening proteinuria. Weight reduction has been associated with improvements in albuminuria and renal parameters, underscoring the therapeutic importance of metabolic optimisation in CKD populations. Beyond metabolic benefits, GLP-1 RAs have demonstrated significant renoprotective effects. Cardiovascular outcome trials – including LEADER, SUSTAIN-6 and REWIND – reported approximately a 21% relative risk reduction in composite renal outcomes, largely driven by decreased progression of albuminuria. The dedicated FLOW trial further confirmed a 24% reduction in major kidney disease events with semaglutide in patients with type 2 diabetes mellitus and CKD, establishing robust evidence for renal benefit on hard clinical endpoints. In patients with advanced CKD awaiting renal transplantation, obesity frequently limits transplant eligibility. GLP-1 RAs provide an effective pharmacologic strategy for weight reduction in this setting, facilitating achievement of institutional body mass index thresholds and potentially preserving residual renal function while on transplant waiting lists. Early observational studies suggest favourable safety and tolerability profiles in CKD stages 3–5 without increased risk of acute kidney injury. Post–renal transplantation, GLP-1 RAs have shown promise in managing new-onset manageable pharmacokinetic considerations with appropriate monitoring. Gastrointestinal adverse effects remain the most common limitation. This narrative review synthesises current evidence regarding the efficacy, safety and clinical applicability of GLP-1 RAs across the CKD spectrum – from pre-dialysis and dialysis populations to transplant candidates and recipients.